Abstract
Type III interferon (IFN) or IFN-λ is a recently discovered family of IFNs that signal through the same downstream transcription factors as type I IFN but use a separate receptor complex composed of the IL-10R2 and the unique IFN-λR1 receptor chains. We have established a simple and efficient expression system to produce highly pure and active IFN-λ of the three human IFN-λ isoforms (IFN-λ1, -λ2 and -λ3) and used this to compare the biological activity of the different IFN-λ subtypes. Surprisingly, we found IFN-λ3 to possess the highest specific activity of the human IFN-λ subtypes, exhibiting a twofold higher activity than IFN-λ1 and a 16-fold higher activity than IFN-λ2. Furthermore, in comparison with the commercially available preparations of IFN-λ1 and -λ2, we found our IFN-λ preparation to be superior in activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 digital issues and online access to articles
$119.00 per year
only $19.83 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Langer JA, Cutrone EC, Kotenko S . The class II cytokine receptor (CRF2) family: overview and patterns of receptor–ligand interactions. Cytokine Growth Factor Rev 2004; 15: 33–48.
Pestka S, Krause CD, Walter MR . Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202: 8–32.
Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD . How cells respond to interferons. Annu Rev Biochem 1998; 67: 227–264.
Young HA, Bream JH . IFN-gamma: recent advances in understanding regulation of expression, biological functions, and clinical applications. Curr Top Microbiol Immunol 2007; 316: 97–117.
Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69–77.
Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE et al. IL-28, IL-29 and their class II cytokine receptor IL-28R 1. Nat Immunol 2003; 4: 63–68.
Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004; 34: 796–805.
Onoguchi K, Yoneyama M, Takemura A, Akira S, Taniguchi T, Namiki H et al. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 2007; 282: 7576–7581.
Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M . Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine 2005; 31: 109–118.
Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R . Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 2007; 81: 7749–7758.
Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR . Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006; 80: 4501–4509.
Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC . Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 2004; 279: 32269–32274.
Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006; 44: 896–906.
Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, Macdonald MR et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887–1898.
Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, Rodia M et al. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun 2007; 8: 254–261.
Jordan WJ, Eskdale J, Boniotto M, Rodia M, Kellner D, Gallagher G . Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun 2007; 8: 13–20.
Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 2006; 12: 1023–1026.
Dunn GP, Koebel CM, Schreiber RD . Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6: 836–848.
Sommereyns C, Paul S, Staeheli P, Michiels T . IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008; 4: e1000017.
Rubinstein S, Familletti PC, Pestka S . Convenient assay for interferons. J Virol 1981; 37: 755–758.
Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, Tian B et al. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 2006; 66: 4468–4477.
Acknowledgements
We thank Susanne Vends for expert technical assistance and Søren Paludan for the kind gift of EMCV and VSV. Also, the advice of Preben Blæsild on statistical treatment of data is highly appreciated. The project was supported by the Novo Nordisk Foundation senior research grant to Rune Hartmann and The Danish Medical Research Council (Grant no: 22-04-0704) and JM was supported by a fellowship from the Danish Medical Research Council (Grant no. 271-05-0632) and a grant from the Lundbeck Foundation.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Genes and Immunity website (http://www.nature.com/gene)
Rights and permissions
About this article
Cite this article
Dellgren, C., Gad, H., Hamming, O. et al. Human interferon-λ3 is a potent member of the type III interferon family. Genes Immun 10, 125–131 (2009). https://doi.org/10.1038/gene.2008.87
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gene.2008.87
Keywords
This article is cited by
-
Interferon lambda in inflammation and autoimmune rheumatic diseases
Nature Reviews Rheumatology (2021)
-
Protective cellular and mucosal immune responses following nasal administration of a whole gamma-irradiated influenza A (subtype H1N1) vaccine adjuvanted with interleukin-28B in a mouse model
Archives of Virology (2021)
-
Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line
BMC Molecular and Cell Biology (2020)
-
Type III Interferons (Lambda Interferons) in Rheumatic Autoimmune Diseases
Archivum Immunologiae et Therapiae Experimentalis (2020)
-
Interferon-λ enhances adaptive mucosal immunity by boosting release of thymic stromal lymphopoietin
Nature Immunology (2019)